FI951681L - Substituoidut N-heteroaroyyliguanidiinit, menetelmä niiden valmistamiseksi niiden käyttö lääkeaineina tai diagnostisena aineena sekä niitä sisältävä lääkeaine - Google Patents

Substituoidut N-heteroaroyyliguanidiinit, menetelmä niiden valmistamiseksi niiden käyttö lääkeaineina tai diagnostisena aineena sekä niitä sisältävä lääkeaine Download PDF

Info

Publication number
FI951681L
FI951681L FI951681A FI951681A FI951681L FI 951681 L FI951681 L FI 951681L FI 951681 A FI951681 A FI 951681A FI 951681 A FI951681 A FI 951681A FI 951681 L FI951681 L FI 951681L
Authority
FI
Finland
Prior art keywords
heteroaroylguanidines
pharmaceuticals
substituted
preparation
pharmaceutical composition
Prior art date
Application number
FI951681A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI951681A0 (fi
FI951681A7 (fi
Inventor
Heinz-Werner Kleemann
Hans-Jochen Lang
Jan-Robert Schwark
Andreas Weichert
Wolfgang Scholz
Udo Albus
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of FI951681A0 publication Critical patent/FI951681A0/fi
Publication of FI951681A7 publication Critical patent/FI951681A7/fi
Publication of FI951681L publication Critical patent/FI951681L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
FI951681A 1994-04-11 1995-04-07 Substituoidut N-heteroaroyyliguanidiinit, menetelmä niiden valmistamiseksi niiden käyttö lääkeaineina tai diagnostisena aineena sekä niitä sisältävä lääkeaine FI951681L (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4412334A DE4412334A1 (de) 1994-04-11 1994-04-11 Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (3)

Publication Number Publication Date
FI951681A0 FI951681A0 (fi) 1995-04-07
FI951681A7 FI951681A7 (fi) 1995-10-12
FI951681L true FI951681L (fi) 1995-10-12

Family

ID=6515052

Family Applications (1)

Application Number Title Priority Date Filing Date
FI951681A FI951681L (fi) 1994-04-11 1995-04-07 Substituoidut N-heteroaroyyliguanidiinit, menetelmä niiden valmistamiseksi niiden käyttö lääkeaineina tai diagnostisena aineena sekä niitä sisältävä lääkeaine

Country Status (16)

Country Link
US (1) US5698581A (fr)
EP (1) EP0676395B1 (fr)
JP (1) JP4171078B2 (fr)
CN (1) CN1073988C (fr)
AT (1) ATE248817T1 (fr)
AU (1) AU683722B2 (fr)
CA (1) CA2146707C (fr)
DE (2) DE4412334A1 (fr)
ES (1) ES2206471T3 (fr)
FI (1) FI951681L (fr)
HU (1) HUT71616A (fr)
IL (1) IL113310A (fr)
NO (1) NO304426B1 (fr)
NZ (1) NZ270894A (fr)
TW (1) TW349941B (fr)
ZA (1) ZA952930B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PL316439A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
DE19548708A1 (de) * 1995-12-23 1997-06-26 Merck Patent Gmbh Cyclische Sulfone
NZ314105A (en) * 1996-02-02 1997-12-19 Sumitomo Pharma Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
DE19605610A1 (de) * 1996-02-15 1997-08-21 Hoechst Ag Substituierte Thiophenylalkenylcarbonsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6136984A (en) * 1996-04-22 2000-10-24 Novo Nordisk A/S Solid phase and combinatorial synthesis of substituted thiophenes and of arrays of substituted thiophenes
JPH09291076A (ja) * 1996-04-24 1997-11-11 Sumitomo Pharmaceut Co Ltd 置換グアニジン誘導体およびその製法
US6344476B1 (en) 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US5994396A (en) * 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
PT1056729E (pt) * 1998-02-27 2005-04-29 Pfizer Prod Inc Derivados de n-[ciclo di- ou tri-aza di-insaturado de cinco membros substituido) carbonil] guanidina para o tratamento de isquemia
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2000042012A1 (fr) 1999-01-13 2000-07-20 Bayer Corporation DIPHENYLUREES A SUBSTITUANTS φ-CARBOXYARYLES, INHIBITRICES DE KINASE RAF
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
MXPA04007830A (es) 2002-02-11 2005-07-01 Bayer Pharmaceuticals Corp Arilureas como inhibidores de cinasa.
WO2003068229A1 (fr) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation N-oxydes de pyridine, de quinoline, et d'isoquinoline en tant qu'inhibiteurs de kinase
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US6803379B2 (en) * 2002-06-04 2004-10-12 Jose A. Fernandez-Pol Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
FR2842524B1 (fr) * 2002-07-16 2005-04-22 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments
WO2004009581A1 (fr) * 2002-07-24 2004-01-29 Mitsui Chemicals, Inc. Procede de production d'un derive 2-alkyl-3-aminothiophene
ATE440827T1 (de) 2002-12-04 2009-09-15 Ore Pharmaceuticals Inc Melanocortin-rezeptormodulatoren
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004113274A2 (fr) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl-urees presentant une activite d'inhibition des kinases
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
WO2005113534A2 (fr) * 2004-05-12 2005-12-01 Schering Corporation Antagonistes de chimiokines cxcr1 et cxcr2
DE102006027229A1 (de) * 2006-06-09 2007-12-20 Grünenthal GmbH 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
US20100113421A1 (en) * 2006-10-06 2010-05-06 Williams Theresa M Non-nucleoside reverse transcriptase inhibitors
CN102482249B (zh) 2009-07-08 2016-06-08 德米拉(加拿大)公司 用于治疗皮肤病症或疾病状态的tofa类似物
EP2602248A1 (fr) 2011-12-05 2013-06-12 University Of Leicester Nouveaux composés pyrroliques
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1053674B (it) * 1968-01-31 1981-10-10 Istituto Farmacobiologico Sero N amidino carbossiamidi ossazoliche ad azione natriuretica
DE1965267C3 (de) * 1968-12-29 1975-07-31 Dainippon Pharmaceutical Co., Ltd., Osaka (Japan) 4-Nitropyrrol-2-carbonsäurehydrazldderivate, Verfahren zu deren Herstellung und deren Verwendung
BE758762A (fr) * 1969-11-12 1971-04-16 Shionogi & Cy Ltd Derives de l'isoxazole et leur preparation
FR2073284B1 (fr) * 1969-12-23 1973-07-13 Ferlux
SU380651A1 (ru) * 1971-05-11 1973-05-15 вители Саратовский государственный университет имени Н. Г. Чернышевского , Саратовский государственный медицинский институт Способ получения гуанидидов фуранкарбоновых или тетрагидрофуранкарбоновых кислот
US4894376A (en) * 1988-02-26 1990-01-16 Trustees Of The University Of Pennsylvania Methods of treating diseases characterized by hyperexcitability of neurons
US5002965A (en) * 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
TW213903B (fr) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
DK0556673T3 (da) * 1992-02-15 1998-04-14 Hoechst Ag o-Substituerede benzoylguanidiner til behandling og profylakse af hjerterytmeforstyrrelser og iskæmisk inducerede skader samt til inhiberering af celleproliferation
ES2089600T3 (es) * 1992-02-15 1996-10-01 Hoechst Ag Benzoilguanidina sustituida en 3,5, con efecto antiarritmico y efecto inhibidor de la proliferacion de celulas.
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
ATE144248T1 (de) * 1992-07-01 1996-11-15 Hoechst Ag 3,4,5-substituierte benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament
DE59305042D1 (de) * 1992-09-22 1997-02-20 Hoechst Ag Benzoylguanidine, Verfahren zu ihrer Herstellung, sowie ihre Verwendung als Antiarrhythmika
PT590455E (pt) * 1992-09-28 2001-04-30 Hoechst Ag 1(2h)-isoquinolinas substituidas anti-arritmicas e cardioprotectoras processo para a sua preparacao medicamento contendo estes compostos e sua utilizacao para a preparacao de um medicamento para o combate de falhas cardiacas
US5260091A (en) * 1992-10-21 1993-11-09 Interneuron Pharmaceuticals Inc. Salt taste enhancers
ES2100435T3 (es) * 1992-12-16 1997-06-16 Hoechst Ag Aminobenzoilguanidinas 3,5-sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene.
CA2121391A1 (fr) * 1993-04-28 1994-10-29 Atsuyuki Kojima Derives d'indoloylguanidine
EP0639573A1 (fr) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant
DE4327244A1 (de) * 1993-08-13 1995-02-16 Hoechst Ag Harnstoffsubstituierte Benzoylguandine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4344550A1 (de) * 1993-12-24 1995-06-29 Hoechst Ag Substituierte 1-Oxo-1,2-dihydro-isochinolinoyl- und 1,1-Dioxo-2H-1,2-benzothiazinoylguanidine, Verfahrenzu ihrer Herstellung, ihre Verwendung als Medikamentt oder Diagnostikum sowie sie enthaltendes Medikamen
TW415937B (en) * 1994-01-25 2000-12-21 Hoechst Ag Phenyl-substituted alkylcarboxylic acid guanidides bearing perfluoroalkyl groups, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4432101A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Aminosäure-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Also Published As

Publication number Publication date
EP0676395A2 (fr) 1995-10-11
JP4171078B2 (ja) 2008-10-22
EP0676395A3 (fr) 1996-03-06
DE59510782D1 (de) 2003-10-09
DE4412334A1 (de) 1995-10-19
IL113310A (en) 2000-06-29
AU1635495A (en) 1995-10-19
FI951681A0 (fi) 1995-04-07
CN1073988C (zh) 2001-10-31
CN1117044A (zh) 1996-02-21
NZ270894A (en) 1997-09-22
CA2146707A1 (fr) 1995-10-12
NO951405D0 (no) 1995-04-10
AU683722B2 (en) 1997-11-20
ZA952930B (en) 1996-01-26
HUT71616A (en) 1996-01-29
NO951405L (no) 1995-10-12
ATE248817T1 (de) 2003-09-15
FI951681A7 (fi) 1995-10-12
JPH07291927A (ja) 1995-11-07
NO304426B1 (no) 1998-12-14
IL113310A0 (en) 1995-07-31
EP0676395B1 (fr) 2003-09-03
CA2146707C (fr) 2008-10-21
ES2206471T3 (es) 2004-05-16
HU9501035D0 (en) 1995-06-28
TW349941B (en) 1999-01-11
US5698581A (en) 1997-12-16

Similar Documents

Publication Publication Date Title
FI951681L (fi) Substituoidut N-heteroaroyyliguanidiinit, menetelmä niiden valmistamiseksi niiden käyttö lääkeaineina tai diagnostisena aineena sekä niitä sisältävä lääkeaine
FI952290A7 (fi) Perfluorialkyylillä substituoidut bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
FI930601A7 (fi) 3,5-substituoidut bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
FI942599A7 (fi) Substituoidut bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
FI946039L (fi) Substituoidut 1-okso-1,2-dihydro-isokinolinoyyli- ja 1,1-diokso-2H-1,2-bentsotiatsinoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
FI954612L (fi) Uusia imidatsolidiinejä, jotka on substituoitu heterosyklillä, niiden valmistusmenetelmä ja -välituotetteita, niiden käyttö lääkkeinä ja niitä sisältävät farmaseuttiset koostumukset
FI935617A7 (fi) 3,5-substituoituja aminobentsoyyliguanidiineja, menetelmä niiden valmistamiseksi, niiden käyttö lääkkeinä tai diagnostisina aineina sekä niitä sisältävä lääke
FI943548A7 (fi) Substituoidut bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
FI952550A7 (fi) Uudet N-pyridyylikarboksamidit ja johdannaiset, menetelmät niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
FI935578L (fi) Substituoidut bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
FI942598A7 (fi) Substituoidut bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
FI943688L (fi) Uudet 11-bentsaldoksiimi-17beta-metoksi-27alfa-metoksi-metyyli-estradieenijohdannaiset, menetelmät niiden valmistamiseksi ja näitä sisältävät lääkeaineet
FI935825A7 (fi) 2,4-substituoidut 5-(N-substituoitu-sulfamoyyli)-bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
FI943716L (fi) Ureasubstituoidut, bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkkeinä tai diagnostisena aineena ja niitä sisältävä lääke
FI935577A7 (fi) Substituoidut bentsoyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkkeinä tai diagnostisina aineina ja niitä sisältävät lääkkeet
FI952117L (fi) Substituoidut bisykliset heteroaroyyliguanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
HUP9802393A3 (en) Benzothiazolone derivatives, their use, pharmaceutical compositions containing them, process for the preparation thereof and intermediates
FI960369L (fi) Emässubstituoituja bentsoyyliguanidiinejä, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävänä lääkkeenä
FI953173L (fi) Orto-aminosubstituoituja bentsolyyliguanidiinejä, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
FI960316L (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
FI960689L (fi) Substituoituja bentseenisulfonyyliureoita ja -tioureoita, menetelmä niiden valmistamiseksi, niiden käyttö lääkkeenä tai diagnostisena aineena sekä niitä sisältävä lääke
FI943853L (fi) Diasyylisubstituoidut guanidiinit, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävä lääkeaine
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
FI954190L (fi) Heterosykli-N-oksidisubstituoituja bentsoyyliguanidiinejä, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä välituotteita niiden valmistamiseksi
HUT77004A (hu) Antiaritmiás szerekként felhasználható nitro-benzamidok, előállításuk és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FD Application lapsed

Free format text: EKA CHEMICALS AB